Cancer is a destructive disease that causes high levels of morbidity and mortality.
Doxorubicin (DOX) is a highly efficient antineoplastic chemotherapeutic drug, but its use …

Cancer remains a major public health problem worldwide and was responsible for 9.6
million deaths in 2018. Oncologic treatments such as doxorubicin (Dox) and trastuzumab …

Doxorubicin (Dox), a widely used chemotherapy drug, can also cause cardiotoxic effects
leading to heart failure. The excessive oxidative stress caused by Dox results in the …

Background Recent studies have shown an association between statin therapy and a
reduced risk of heart failure among breast cancer survivors. Our goal was to evaluate …

Anthracycline anticancer drugs, such as doxorubicin (DOX), can induce cardiotoxicity
supposed to be related to mitochondrial damage. We have recently demonstrated that a …

Breast cancer is the most common cancer in the UK. Advances in the methods of early
diagnosis as well as newer and more effective treatments have led to improvements of …

Background: Although the combination of doxorubicin (DOX) and trastuzumab (TRZ)
reduces the progression and recurrence of breast cancer, these anticancer drugs are …

Background In the breast cancer setting, anticancer therapies including doxorubicin (DOX)
and trastuzumab (TRZ) are associated with a significantly increased risk of cardiotoxicity …

The recent introduction of novel anticancer therapies, including bevacizumab (BVZ) and
sunitinib (SNT), is associated with an increased risk of cardiotoxicity. However, early …

The continuous development of antineoplastic therapy has significantly reduced the
mortality of patients with malignant tumors, but its induced cardiotoxicity has become the …